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Abstract  
 
Objective: Our aim was to improve meta-analysis methods for summarising a prediction 
model’s performance when individual participant data are available from multiple studies for 
external validation. 
  
Study design & setting: We suggest multivariate meta-analysis for jointly synthesising 
calibration and discrimination performance, whilst accounting for their correlation. The 
approach estimates a prediction model's average performance, the heterogeneity in 
performance across populations, and the probability of ‘good’ performance in new 
populations. This allows different implementation strategies (e.g. recalibration) to be 
compared. Application is made to a diagnostic model for deep vein thrombosis (DVT) and a 
prognostic model for breast cancer mortality. 
 
Results: In both examples multivariate meta-analysis reveals that calibration performance is 
excellent on average, but highly heterogeneous across populations unless the model’s 
intercept (baseline hazard) is recalibrated. For the cancer model, the probability of 'good' 
performance (defined by C-statistic≥0.7 and calibration slope between 0.9 and 1.1) in a new 
population was 0.67 with recalibration, but 0.22 without recalibration. For the DVT model, 
even with recalibration there was only a 0.02 probability of 'good' performance.  
  
Conclusion: Multivariate meta-analysis can be used to externally validate a prediction 
model’s calibration and discrimination performance across multiple populations, and to 
evaluate different implementation strategies.  
 
Keywords 
Risk prediction; prognostic model; individual participant data (IPD); multivariate meta-
analysis; external validation; calibration; discrimination; heterogeneity; model comparison  
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What is new? 
 
KEY FINDINGS 
 
Given individual participant data (IPD) from multiple external validation studies, meta-
analysis enables researchers to summarise prediction model performance, in terms of both 
average performance and consistency in performance across populations. It thereby allows 
different implementation strategies (e.g. recalibration) to be formally compared. 
 
A multivariate meta-analysis approach should be used to jointly evaluate discrimination and 
calibration performance, whilst accounting for their correlation. This can be used within 
internal-external cross-validation (to also incorporate a model development phase), or when 
IPD from multiple studies are available for external validation of existing models. 
 
WHAT THIS ADDS TO WHAT IS KNOWN: 
 
Before implementation, risk prediction models require validation in data external to that used 
for model development. This is best achieved using IPD from multiple studies, so that model 
performance can be examined and quantified across multiple populations of interest. A good 
prediction model will have satisfactory performance on average across all external validation 
datasets, and crucially little or no between-study heterogeneity in performance.  
 
Our examples show that a prediction model may have excellent average performance, but 
with heterogeneity (inconsistency) in performance across populations. Recalibration of the 
model’s intercept term (or baseline hazard) in the intended population might reduce 
heterogeneity, and thereby improve the probability of acceptable model performance when 
applied in new populations.   
 
WHAT IS THE IMPLICATION, WHAT SHOULD CHANGE NOW: 
 
When IPD are available from multiple studies for external validation of a prediction model, 
researchers should use multivariate meta-analysis to jointly summarise calibration and 
discrimination performance, and to identify how best to implement the model in new 
populations.  
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1. Introduction 
A crucial part of medical research is to develop risk prediction models. These aim to 
accurately predict disease and outcome risk in individuals [1-3], thereby informing clinical 
diagnosis and prognosis. For example, healthy individuals with a high predicted risk of future 
disease (e.g. cardiovascular events) may be advised to modify their lifestyle and behaviour 
choices (e.g. smoking, exercise), and diseased individuals may be grouped (e.g. stage of 
cancer) according to future outcome risk so that clinical decisions (such as treatment options, 
monitoring strategies) can be tailored accordingly. Two well-known examples are QRISK [4] 
and the Nottingham Prognostic Index [5]. They are typically implemented within a 
multivariable regression framework, such as logistic or Cox regression, which provides an 
equation to estimate an individual's risk based on values of multiple predictors (prognostic 
factors [6]) such as age, biomarkers, and genetic information  
 
A key stage of prediction model research is model development [2]. This identifies important 
predictors and develops the risk prediction equation using an available dataset; it usually also 
examines the model's apparent performance in this same data, or uses internal validation 
techniques (such as bootstrap resampling) to examine and adjust for optimism in performance 
[7]. The next stage is external validation [8-10]. This uses data external to the model 
development data and its source, and examines whether the model predictions are accurate in 
another (but related) situation. The aim is to ascertain the model's generalisability to the 
intended populations for use [11], and to identify the best implementation strategy (e.g. 
recalibration of the intercept).  
 
Unfortunately, most prediction research focuses on model development and there are 
relatively few external validation studies [12]. However, nowadays there is increasing access 
to multiple datasets, as evident in meta-analyses using individual participant data (IPD) from 
multiple studies [13, 14]. This provides an exciting opportunity to perform external validation 
on multiple occasions [15, 16]. Model development and external validation can even occur 
simultaneously, using an approach called internal-external cross-validation [17, 18]. This 
develops a model in all but one of the IPD studies, and then its external validity is 
immediately checked in the omitted study. This process is repeated across all rotations of the 
omitted study, to measure external validity in each distinct IPD study.  
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Given multiple external validation studies, meta-analysis methods are needed to synthesise 
and summarise model performance appropriately across the available populations. Van 
Klaveren et al.[16], Pennells et al.[15] and, within internal-external cross-validation, Royston 
et al.[17] consider approaches to summarise validation performance across multiple studies or 
clusters. These focus mainly on producing pooled estimates of discrimination performance; 
that is, a model’s ability to distinguish correctly between patients with and without the 
outcome of interest. Researchers should also be interested in summarising calibration 
performance, which is the agreement between a model’s predicted risk and the observed risk. 
Calibration is often ignored in external validation research [19], even though it is 
fundamental that observed and predicted risks should closely agree. Moreover, baseline risk 
may vary across study populations and so a model's implementation may need to be tailored 
to each population (often referred to as recalibration) in order to improve calibration 
performance in new populations. 
 
In this article, we propose multivariate meta-analysis for jointly synthesising discrimination 
and calibration performance, whilst accounting for their correlation. This can be used within 
internal-external cross-validation (to also incorporate a model development phase), or when 
IPD from multiple studies are available for external validation of existing models. We show 
that the multivariate approach summarises a prediction model's average discrimination and 
calibration performance, and quantifies the heterogeneity in performance across populations. 
It also allows researchers to predict the potential calibration and discrimination of a model 
when it is applied to a new population, and can be used to estimate the probability of ‘good’ 
performance (as pre-defined by the user). Using two real examples, we illustrate how this 
enables researchers to compare the performance of different implementation strategies (e.g. 
recalibration of the intercept term) to help identify the best strategy for applying the model in 
practice. 
  
The article now proceeds by introducing the proposed multivariate meta-analysis 
methodology for summarising and comparing validation performance (Section 2). Two 
clinical examples are then used to illustrate the approach (Section 3), one for diagnosis and 
one for prognosis, and we conclude with some discussion (Section 4). 
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2. Meta-analysis of predictive performance statistics from multiple 
external validation studies 
External validation of a prediction model requires evaluation of its predictive performance, in 
terms of both calibration and discrimination. There are many statistical measures available 
for this purpose [1, 20]. Here we focus on those most commonly used: the C-statistic [20, 21] 
the D-statistic [22, 23], the calibration slope [1, 20], calibration-in-the-large [1], and the 
Expected/Observed number of events. These are defined in the Appendix. We focus here on 
how to meta-analyse such performance statistics when they are estimated in multiple external 
validation studies. 
 
2.1 Obtaining suitable data for meta-analysis 
The meta-analysis approach requires an estimate of each performance statistic of interest (e.g. 
C-statistic, calibration slope) from each external validation study. Given IPD, these can be 
calculated in each validation study using appropriate statistical methods, as described 
elsewhere [1, 20, 23]. However, meta-analysis also requires the variance-covariance matrix 
of the performance statistics in each study: in other words, the variance of each performance 
estimate and (for multivariate meta-analysis) the correlation between all pairs of estimates. A 
general approach to obtaining these is via non-parametric bootstrapping, as described in the 
Appendix.  
 
2.2 Univariate random-effects meta-analysis 
For clarity, before proposing our multivariate approach we firstly describe a univariate 
random-effects meta-analysis that is applicable separately to each performance measure of 
interest[24, 25]. In external validation study i let Yij be the estimate of the jth performance 
statistic of interest, and let  Sij2  be its sample variance (derived from bootstrapping and 
assumed known), then the univariate meta-analysis can be written as: 
  
 
Yij ~ N ,	Sij2 
μij ~ N ,	
  
(1)  
 
Equation (1) assumes the Yij are normally distributed about the ith study's true validation 
performance, μij, and that the μij are also normally distributed with an average of  and a 
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between-study standard deviation of 	. There are several frequentist methods that can be 
used for estimation of a random-effects meta-analysis; here we use restricted maximum 
likelihood (REML)[26]. With the addition of prior distributions for unknown parameters, a 
Bayesian approach is also possible, for example using Gibbs sampling. An approximate 
100(1-α)% confidence interval for the average performance, , is obtained by 
̂ ±1.96 SE(̂), where SE(̂) is the standard error of ̂ . White [27] proposed that SE(̂) is 
inflated to account for the uncertainty in the estimated 	, and we implement this here. 
 
Summarising consistency in model performance 
On its own, ̂ is an incomplete summary because it does not adequately summarise the 
consistency in performance across studies. Estimates such as 
 (the percentage of the total 
variation in study estimates that is due to between-study heterogeneity [28]) and  	̂
	are thus 
also helpful [29]. However, when evaluating performance statistics of a risk prediction model 
we are examining its generalisability, in other words its robustness when applied in new 
populations that differ from those it was developed in [11]. Thus, consistency is best 
expressed by a 100(1-)% prediction interval for the performance of the model in a new 
population [24, 25]. This is derived by 
 ̂ ± t∝,	N - 2	̂
  +V(̂)  (2)  
where t∝, N - 2 is the 100 1- ∝2 	% percentile of the t-distribution for N - 2 degrees of freedom 
(N = no. of studies), V(̂) =SE(̂)
, and ∝  is typically taken to be 0.05 to give a 95% 
interval. The use of a t-distribution, rather than a normal distribution, is used to account for 
the uncertainty in 	̂
 [24]. The prediction interval thus indicates the performance expected in 
a new (external validation) study, similar to those included in the meta-analysis. 
 
2.3 Multivariate meta-analysis 
Our multivariate approach is an extension of equation (1)[30], and allows the joint synthesis 
of all predictive performance measures of interest from the i = 1 to N external validation 
studies, whilst accounting for their within- and between-study correlation. Let there be j = 1 
to J measures of interest, and let iY  be a vector containing the available J estimates (
iJii ,Y,,YY K21 ) of the measures in the ith validation study. The general multivariate meta-
analysis model is as follows: 
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( )
( )Σµθ
SθθY
i
iiii
,~
,~
MVN
MVN| 
  
 
Here MVN denotes a multivariate normal distribution, iθ  contains the true underlying effects 
for the J performance measures for the ith study, iS  is the within-study variance-covariance 
matrix for the ith study (assumed known) containing the J variances of the estimates (in the 
diagonal: 222
2
1 iJii ,S,,SS K ) and their covariances (in the off-diagonal; for example 2121 ii),Wi( SSρ  
is the within-study covariance for measures 1 and 2, where ),Wi(ρ 21 is their within-study 
correlation caused by estimates derived from the same patients), µ  contains the J means for 
the measures of interest, and Σ  is the between-study variance-covariance matrix containing 
the J between-study variances (in the diagonal: 22221 J,τ,,ττ K ) and their between-study 
covariances (in the off-diagonal; e.g. the between-study covariance for measures 1 and 2 is 
2121 ττρ ),(B , where ),(Bρ 21  is their between-study correlation induced by differences in study 
populations and settings). The number of rows in each vector is equal to the number of 
measures. In its simplest form with two measures of interest (e.g. C-statistic and calibration 
slope), equation (3) can be expressed as a bivariate meta-analysis (Appendix).  
 
 
REML can again be used for estimation, although other options are available [30, 31]. 
Multivariate extensions to 
 can also be calculated [26, 31], giving the fraction of the total 
variability due to between-study variability for each performance statistic (
).  
 
Making joint inferences across multiple performance measures 
After equation (3) is estimated, marginal confidence and prediction intervals for each 
performance measure can be obtained using the formulae given in the univariate section. 
However, by accounting for their correlation, the multivariate approach also enables joint 
inferences. For instance, extending equation (2) to a bivariate t-distribution with k – 2 degrees 
of freedom, one can obtain a joint 95% prediction region for two performance measures of 
interest (e.g. the C-statistic and the calibration slope) in a new population. Joint probabilistic 
inferences can also be made if we assume the multivariate t-distribution is an approximate 
posterior distribution (that is, we assume it is obtained from a Bayesian analysis with 
uninformative priors, and give it means, variances and covariances obtained from REML 
(3) 
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estimation of equation (3) - see Supplementary material 1 for full details [32]). For example, 
one can derive the joint probability that the C-statistic will be above 0.7 and the calibration 
slope will be between 0.9 and 1.1 in a new population. A fully Bayesian approach can also be 
used to derive such posterior inferences by formally specifying prior distributions and 
combining them with the likelihood, then using, for example, Gibbs sampling to take samples 
from the exact posterior distributions. Riley et al.[33] describe the Bayesian approach to 
multivariate meta-analysis with IPD. 
 
2.4 Comparing the predictive performance of different implementation strategies 
When applying a prediction model to a new population, different implementation strategies 
might be used regarding the choice of model intercept (baseline hazard) (this is illustrated in 
Sections 3.1 and 3.2, and for example includes recalibration). Meta-analysis of performance 
statistics allows such implementation strategies to be formally compared. The aim is to 
identify an implementation strategy that, for each performance measure, has excellent 
performance on average (indicated by ̂); small values of between-study heterogeneity 
(indicated by 	̂ and/or 
); and a narrow prediction interval that suggests consistently good 
performance in new populations. Multivariate meta-analysis even allows the competing 
strategies to be ranked according to their overall performance: for example, according to the 
joint probability that, in a new population, the C-statistic will be above 0.7 and the calibration 
slope will be between 0.9 and 1.1. The strategy with the largest probability will be ranked 
first.  
 
2.5 Meta-regression and examining covariates 
Meta-analysis equation (3) can be extended to a multivariate meta-regression that includes 
study-level covariates to explain between-study heterogeneity, such as treatment policies, 
population characteristics (e.g. mean age), year of investigation, and length of follow-up. 
Competing implementation strategies can then be evaluated and compared for specific 
subgroups of studies (e.g. those done within the last few years, those with consistent 
treatment policies, those with the same case-mix, etc). This may help identify populations 
where model performance is satisfactory and others where it is inadequate, to inform the 
model's generalisability and applicability [11]. A nice example of a meta-regression to 
examine the impact of case-mix variation on model performance is given by Pennells et al. 
[15], who identify that studies with a higher standard deviation of age are strongly associated 
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with a higher C-statistic and D-statistic. Model performance can also be examined for patient-
level covariates; for example, discrimination and calibration could be estimated for males and 
females separately. Equation (3) can then be applied to summarise each subgroup, or even the 
difference between subgroups. 
 
3. Applied examples 
We now illustrate the proposed meta-analysis methods with two applied prediction model 
examples, one for diagnosis and one for prognosis, and compare the performance of different 
implementation strategies, including recalibration 
 
3.1 Diagnostic example: Prediction of existing deep vein thrombosis 
Data, model development and competing implementation strategies 
We used IPD from 12 studies to develop a diagnostic prediction model for the risk of having 
deep vein thrombosis (DVT) in patients that were suspected of having DVT, as described 
previously [34]. A total of 10002 patients were available across the 12 studies (with study 
sample sizes ranging from 153 to 1768 patients), and 1864 (19%) patients truly had DVT. 
This IPD is used here only for illustration purposes and not to develop or recommend the 
optimal diagnostic model to be used in medical practice.  
 
The prediction model was developed using logistic regression, including a separate intercept 
for each study and three predictors chosen a priori: sex (male=1, female=0), surgery (recent 
surgery or bedridden = 1, no recent surgery or bedridden = 0) and calf difference (≥3cm = 1, 
<3cm = 0). However, three different implementation strategies were considered (for the 
model intercept) when applying the developed model to the external validation dataset: 
Strategy (1): Use a new intercept estimated in the external validation dataset itself. 
This is a form of model recalibration [35]. 
Strategy (2): Use the estimated weighted average of the study intercept terms from 
the developed model. 
Strategy (3): Use the estimated intercept for one of the studies in the developed 
model that had the most similar prevalence of DVT to the external 
validation study. 
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Internal-external cross-validation was undertaken for each implementation strategy, and their 
predictive performance then summarised and compared across the 12 external validation 
studies using our multivariate meta-analysis approach. 
 
Results 
Regardless of which study was excluded, the predictor effect estimates (log odds ratios) were 
very similar in each cycle of the internal-external cross-validation approach (supplementary 
material 2 shows the parameter estimates in each cycle, and the intercept to be implemented 
in strategy (3)). During external validation of the model, for each implementation strategy 
four validation statistics were estimated: calibration-in-the-large, calibration slope, the C-
statistic, and the ratio of expected and observed DVT cases, as defined in the Appendix. 
These results are shown (with standard errors) in supplementary material 3(a) for each of the 
strategies. Their within-study correlations, obtained from bootstrapping with 1000 samples, 
are shown in supplementary material 3(b). These are large (between +0.90 to +0.98) for the 
calibration slope and C- statistic, indicating a strong positive relationship between them. In 
other words, as the observed calibration slope of model predictions decreases (becomes 
flatter) the observed discrimination of the model predictions also decreases (less separation); 
conversely, when model predictions produce a steeper observed calibration slope the 
discrimination is improved. The other measures of calibration (calibration-in-the-large and 
expected/observed) measure overall agreement, and thus are not affected so much by changes 
in discrimination; thus their within-study correlation with the C-statistic is close to zero. 
There is a perfect negative correlation between log(expected/observed) and calibration-in-
the-large by definition. 
 
The multivariate meta-analysis results for each statistic are shown in Table 1. The meta-
analysis results for the C-statistic are practically the same in all implementation strategies, as 
are those for the calibration slope. The mean C-statistic is 0.69 (95% CI: 0.67 to 0.71), 
indicating moderate discrimination. There is a small amount of between-study heterogeneity 
(τ̂≈0.02; I2 ≈37%), leading to a 95% prediction interval of 0.64 to 0.73, revealing fairly 
consistent discrimination performance across studies (Figure 1). The mean calibration slope 
is around 0.98 (95% CI: 0.85 to 1.10), which is close to the ideal value of one though 
indicating very slight over-prediction. The amount of between-study heterogeneity is large 
(	̂≈0.16; I2 ≈59%), leading to a wide 95% prediction interval (e.g. 0.59 to 1.38 for strategy 
(2)). This contains values well above and well below one, which respectively suggest that in 
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some populations the predicted probabilities vary too little (i.e. the model is under-fitted 
and/or assigns probabilities that are too similar across individuals) and in others they vary too 
much (i.e. the model is over-fitted to the development sample and assigns probabilities that 
vary too much across individuals). This illustrates how the average performance is an 
incomplete picture; calibration slope is good on average, but could be poor in particular 
populations (Figure 2). 
 
Calibration-in-the-large does differ more importantly across implementation strategies (Table 
1), as it is sensitive to the choice of intercept. The meta-analysis results reveal it is, on 
average, slightly worse for strategy (1) as there is a small over-prediction in the proportion 
with DVT (-0.13, 95% CI: -0.19 to -0.08).  However, there is almost no heterogeneity in the 
calibration-in-the-large (τ̂=0.008; I2 =1%), leading to a narrow 95% prediction interval (-0.20 
to -0.07). Using strategy (2) or (3) the average calibration-in-the-large is closer to zero           
(-0.004 and 0.047 respectively), but comes at the expense of slightly larger between-study 
heterogeneity (τ̂=0.53 and 0.27, I2 =97% and 89% respectively), leading to wider prediction 
intervals. For example, for strategy (2) the 95% prediction interval is -1.24 to 1.23.  
 
Instead of calibration-in-the-large, it is perhaps easier to interpret the Expected/Observed 
proportion of DVT cases (Table 1). This follows a similar pattern (Table 1), with narrowest 
prediction interval for strategy (1) and slightly improved average performance for strategies 
(2) and (3). The 95% prediction interval for Expected/Observed for strategy (1) suggests the 
overall agreement is likely to be reasonable in new populations (1.05 to 1.14), with the 
number of DVT cases over-predicted by between 5% and 14%. However, the 95% prediction 
interval is unsatisfactory for the other strategies; for example, it is 0.41 to 2.54 for strategy 
(2) indicating the number of predicted DVT cases in a new population could range from 59% 
too few up to 154% too many. 
 
Overall, therefore, strategy (1) appears best as it removes heterogeneity in the calibration-in-
the-large and Expected/Observed, whilst maintaining similar discrimination. However, the 
prediction model would benefit from additional predictors, as currently discrimination is only 
moderate and there is large heterogeneity in calibration slope. This is confirmed by a joint 
probability of only 0.03 that strategy (1) will give a C-statistic ≥ 0.7 and a calibration slope 
between 0.9 and 1.1 in a new population (Table 2). If the criteria for model discrimination is 
relaxed to a C-statistic ≥ 0.65, then the joint probability improves but only to 0.43.  
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3.2 Prognostic example: Prediction of mortality in breast cancer patients 
Data, model development, and competing implementation strategies 
We used IPD from eight cohort studies (relating to eight different countries from Look et 
al.[36]) to develop and evaluate a prognostic prediction model for the risk of mortality over 
time in women recently diagnosed with breast cancer. In total there were 7435 patients 
(ranging from 69 patients to 3242 per study) and 2043 events. The maximum follow-up 
duration was 120 months and the median follow-up duration across all studies was 86.3 
months. Internal-external cross-validation was used and, in each cycle, a Royston-Parmar 
flexible parametric survival model was fitted [37-39], with the baseline cumulative hazard 
function modelled using restricted cubic splines (with four knots deemed sufficient) and 
predictor effects (hazard ratios) assumed constant over time. A set of eight candidate 
predictors was considered at each cycle: age, tumour type, tumour grade, tumour size, 
number of positive nodes, menopausal status, adjuvant therapy, and hormone receptor status. 
Backwards selection was used, with p>0.05 taken for exclusion. Separate but proportional 
baseline hazard functions were included for each country; that is, one study was taken as the 
reference group, and others were allowed a country-specific adjustment factor). When 
applying the developed model to the external validation study, three different implementation 
strategies were considered (in regard the baseline hazard): 
 
Strategy (1): Use a new country-specific adjustment factor as estimated in the 
validation study itself. This is a form of recalibration, but assumes the 
baseline hazard in the validation study and the development studies are 
proportional.  
Strategy (2): Use a weighted average of the estimated country-specific adjustment 
factors from the developed model.  
 Strategy (3):  Use the country-specific adjustment factor for a country that was 
included in the developed model and is closest geographically to the 
validation country. 
 
Internal-external cross-validation was undertaken for each strategy, and their predictive 
performance then summarised and compared across the eight external validation studies 
using meta-analysis. 
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Results 
The predictor effect estimates (log hazard ratios) were similar in each cycle of the internal-
external cross-validation approach (results available on request). The backwards selection 
retained all candidate predictors in each cycle, apart from menopausal status which was 
always excluded.  For each implementation strategy, we evaluated model performance in 
each external validation study by estimating Harrell's C-statistic [20], the D-statistic [22, 40], 
and the calibration slope between the predicted hazard function and the observed hazard 
function, as defined in the Appendix. The estimates, with their variances and within-study 
correlation, are shown in supplementary material 4. Within-study correlations were all 
positive, and generally moderate to large. 
  
Multivariate meta-analysis of the validation statistics is summarised in Table 3 for each 
implementation strategy. The summary C-statistic and D-statistic results are barely affected 
by the choice of strategy. The average C-statistic is 0.71 and its 95% prediction interval is 
0.66 to 0.76, suggesting consistently moderate discrimination across populations. The 
average D-statistic is about 0.33, which equates to a moderate hazard ratio of 1.39 (95% CI: 
1.23 to 1.57) between two equal sized groups across the prognostic index. However, D is 
inconsistent across populations (I2 is about 87%), and thus its prediction interval is wide 
(Table 3).  
 
Calibration slope is affected by the choice of strategy. For strategy (1), which allows 
recalibration in the validation study, the calibration slope is excellent. The meta-analysis 
gives an average calibration slope of 1.003, with only moderate heterogeneity (I2 = 35%) 
leading to a narrow prediction interval of 0.93 to 1.08. In contrast, strategies (2) and (3) 
perform poorly. Although average calibration is excellent, there is large between-study 
heterogeneity (e.g. I2 = 99% for strategy (3)) leading to wide predictions intervals (e.g. 0.15 
to 1.77 for strategy (3)). This again reveals how average performance is an incomplete and 
potentially misleading summary of performance.  
 
Figure 3 shows joint prediction ellipses for the C-statistic and the calibration slope, derived 
using the multivariate meta-analysis results for each strategy. For implementation strategy (1) 
there is a joint probability of 0.67 for a C-statistic ≥ 0.7 and a calibration slope between 0.9 
and 1.1; however, the probability is only 0.15 for strategy (3) and 0.22 for strategy (2).  
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Strategy (1) thus performs best, but it requires recalibration of the model in new countries and 
may be difficult to implement. We therefore sought to improve strategy (2), which does not 
include recalibration, by identifying the cause of heterogeneity in its calibration performance. 
It was observed that Study 3 gave the poorest calibration slope upon external validation of the 
models (Table 4), most likely due to the baseline hazard in Study 3 being different in shape 
(non-proportional) to those other studies. Extending equation (3) to a multivariate meta-
regression with a covariate for country (1= Study 3, 0 = otherwise) explained a large part of 
the heterogeneity (p < 0.001). We repeated the internal-external cross-validation approach for 
strategy (2), but omitted Study 3 for the entire process. External validation performance was 
improved, as heterogeneity in calibration slope was reduced (τ̂ = 0.156 excluding Study 3, τ̂ = 
0.22 including Study 3), and thus its 95% prediction interval was narrower (supplementary 
material 5). The joint probability for a C-statistic≥0.7 and a calibration slope between 0.9 and 
1.1 was improved to 0.32, but still considerably worse than strategy (1), indicating 
recalibration remains preferable.  
 
4.  Discussion  
We have proposed a multivariate meta-analysis approach for summarising and comparing 
prediction model performance across multiple external validation studies using IPD. This can 
be used within internal-external cross-validation to also incorporate a model development 
phase, or when IPD from multiple studies are available for external validation of existing 
models. Each of the statistical methods involved (such as obtaining within-study correlations 
and fitting the multivariate equation) only take up to a few minutes to perform using 
computer software such as STATA, and provide results that improve the interrogation of a 
prediction model’s performance and its implementation strategy.  
 
Currently, most external validation research is undertaken using a single dataset. However, 
multivariate meta-analysis of IPD is a novel way to examine the overall performance and 
generalisability of a prediction model across multiple datasets[13, 15, 16]. A good model will 
have satisfactory performance on average across all external validation datasets. But ideally 
there should also be little or no between-study heterogeneity in performance. Our examples 
showed that a prediction model may have excellent average performance, but may not have 
consistent performance across datasets. Such heterogeneity is rarely considered in external 
validation research, but should be routinely examined where possible, in particular to identify 
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the best implementation strategy. In our examples, the investigation of heterogeneity revealed 
that recalibration of the intercept term to the validation population was essential, otherwise 
there was considerable inconsistency in calibration performance of our prediction models. 
The importance of intercept recalibration is also shown elsewhere [41, 42]. However, it may 
not entirely remove the issue of miscalibration, as seen in the DVT example where there 
remained slight over-prediction even after recalibration. In particular, if there is also 
heterogeneity in predictor effects then one may also need to recalibrate these to the intended 
population; however, this defeats the purpose of the initial research (i.e. to develop a 
prediction model that can be used widely and easily), and rather indicates that additional 
and/or more homogenous predictors are required. 
  
Heterogeneity in discrimination performance was also observed in our examples. This may 
also be due to heterogeneity in predictor effects across populations and/or different case-mix 
distributions across populations, as populations with wider ranges of continuous predictors 
often have better discrimination[15]. For such reasons, incorporating matched case-control 
studies alongside cohort studies may increase heterogeneity in discrimination performance, as 
the former typically have narrower ranges of predictors [43]. Another potential cause of 
heterogeneity in performance of a prognostic prediction model is follow-up time, and also 
heavy censoring may bias Harrell’s C-statistic, prompting Gönen and Heller to propose an 
alternative [44]. Such factors may also impact the magnitude of between-study correlation in 
the performance measures.  
 
As external validation of a prediction model usually requires multiple statistical measures of 
performance, in particular at least one for calibration and one for discrimination [8, 19], our 
multivariate meta-analysis approach jointly synthesises all measures together across multiple 
validation studies. This accounts for their within-study and between-study correlation [45], 
which may arise because measures are highly related [33]. For example, the C-statistic and 
D-statistic typically have moderate to large positive within-study correlation (as seen in 
supplementary material 4(b)) as they are both measures of discrimination and within-studies 
are estimated on the same patients. Similarly the calibration slope and C-statistic may also be 
correlated between-studies, for instance if the between-study heterogeneity in predictor 
effects causes calibration slope to become greater than 1 as discrimination improves, but less 
than 1 as discrimination worsens. Accounting for such correlation in the meta-analysis allows 
the borrowing of strength across performance measures to potentially reduce bias and 
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improve precision [46, 47]. Further, it is crucial to account for correlation when computing 
joint probabilities of model performance, such as the magnitude of the C-statistic and 
calibration slope, as otherwise inferences may be misleading [45].  
 
Our intention was to illustrate how the multivariate meta-analysis approach allows 
researchers to summarise both discrimination and calibration. We focused on well-known 
statistical criteria, such as the calibration slope, (Harrell’s) C-statistic, and Royston and 
Sauerbrei’s D-statistic. However, we recognise that the criteria for a 'good' prediction model 
is open to much debate [48], and readers may prefer to meta-analyse other statistical 
measures available, including alternatives to Harrell’s C-statistic [44]. Clinical criteria may 
also be preferred [49], to focus more on the consequences for decision-making [50].Whatever 
criteria are used, we recommend they are pre-specified in a published protocol [51]. Visual 
plots of calibration [23] and discrimination [52] are also important, as neatly illustrated by 
Royston et al.[17]. Calibration estimates can also be obtained (and then meta-analysed) for 
particular subgroups within studies, for example defined by particular patient characteristics 
or categories of the prognostic index [23]. Also, we note that excellent validation 
performance is not the end of the story: a prediction model’s impact on patient outcomes also 
needs to be evaluated, for example in subsequent trials[3].  
 
A potential limitation of our work is the multivariate normality assumption for the 
distribution of true performance across studies. Though this is a common assumption in the 
meta-analysis field, prediction intervals and regions are potentially vulnerable to departures 
from this[53]. A related issue is the choice of scale to use for the estimates of validation 
performance[16], and further research is needed on this. Internal-external cross-validation is 
also limited if the number of studies are small, and researchers should ensure the number of 
events is suitable in each cycle [54, 55].  
 
In conclusion, we propose multivariate meta-analysis for external validation of the 
performance and implementation of a prediction model when IPD are available for multiple 
studies. The approach encourages researchers to focus not only on average performance, but 
also on the consistency in performance across populations, for both calibration and 
discrimination. 
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Table 1: Trivariate meta-analysis results* for the calibration and discrimination performance of the DVT model for each implementation 
strategy. 
  
Strategy Validation statistic 
Estimate (95% CI) of mean, 
μ 
95% prediction interval I2 %   (95% CI ) 
Strategy (1): 
Develop using logistic 
regression and implement 
with intercept estimated in 
external validation study 
Calibration-in-the-large -0.130 (-0.185 to -0.075) -0.195 to -0.065 1 0.008 
Calibration slope 0.975 (0.855 to 1.097) 0.597 to 1.353 57 0.158 
Log(Expected/Observed) 0.086 (0.047 to 0.124) 0.041 to 0.128 0 0.0009 
C-statistic 0.687 (0.670 to 0.704) 0.645 to 0.729 34 0.017 
Strategy (2): 
Develop using logistic 
regression and implement 
with average study intercept 
taken from developed model 
Calibration-in-the-large -0.004 (-0.313 to 0.305) -1.240 to 1.232 97 0.532 
Calibration slope 0.980 (0.853 to 1.107) 0.585 to 1.375 59 0.165 
Log(Expected/Observed) 0.022 (-0.206 to 0.250) -0.887 to 0.931 97 0.391 
C-statistic 0.687 (0.669 to 0.705) 0.640 to 0.734 37  0.019 
Strategy (3): 
Develop using logistic 
regression and implement 
with intercept taken from a 
study used in development 
data with a similar prevalence 
Calibration-in-the-large 0.047 (-0.120 to 0.214) -0.584 to 0.678 89  0.270 
Calibration slope 0.976 (0.851 to 1.102) 0.578 to 1.375 59  0.167 
Log(Expected/Observed) -0.029 (-0.150 to 0.093) -0.485 to 0.427 89  0.195 
C-statistic 0.687 (0.669 to 0.705) 0.640 to 0.734 38 0.019 
 
 
*  A trivariate meta-analysis was fitted to calibration-in-the-large, calibration slope and C-statistic, and then again for log(Expected/Observed), 
calibration slope, and C-statistic. Perfect negative correlation between calibration-in-the-large and expected/observed within studies prevents all 
four measures being analysed together (due to collinearity). Results were practically the same for calibration slope and C-statistic, regardless of 
the trivariate model fitted.              
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Table 2: Joint predicted probability of 'good' discrimination and calibration performance for 
each of the three DVT models, derived using the multivariate meta-analysis results for the C-
statistic and calibration slope shown in Table 1.  
 
Calibration 
slope 
required 
Minimum  
C-statistic 
required 
Joint predicted probability of meeting criteria in new population 
Strategy (1):  
Develop using logistic 
regression and 
implement with 
intercept estimated in 
external validation 
study 
Strategy (2):  
Develop using 
logistic regression 
and implement with 
average study 
intercept taken from 
developed model 
Strategy (3):  
Develop using logistic 
regression and implement 
with intercept taken from 
a study used in 
development data with a 
similar prevalence 
0.9 to 1.1 0.70 0.027 0.037 0.037 
0.8 to 1.2 0.70 0.146 0.158 0.156 
0.9 to 1.1 0.65 0.427 0.413 0.409 
0.8 to 1.2 0.65 0.728 0.712 0.707 
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Table 3: Trivariate random-effects meta-analysis results for calibration and discrimination 
performance of the breast cancer model for each implementation strategy 
Strategy Validation 
statistic 
Pooled estimate 
(95% CI) 
95% 
prediction 
interval 
I-
squared 
Estimate 
of τ 
Joint 
probability 
of 'good'* 
performance 
in a new 
population 
Strategy (1):  
Develop using 
Royston-Parmar model 
and implement with 
baseline hazard 
estimated in validation 
study 
Calibration 
slope 
1.003 (0.971 to 
1.036) 
0.927 to 
1.080 
35% 0.026 
0.67 
C-statistic 0.711 (0.690 to 
0.733) 
0.657 to 
0.766 
49% 0.019 
D-statistic 0.328 (0.215 to 
0.442) 
-0.056 to 
0.713 
87% 0.146 
Strategy (2):  
Develop using 
Royston-Parmar model 
and implement with the 
estimated average 
baseline hazard from 
developed model 
Calibration 
slope 
0.994 (0.835 to 
1.153) 
0.411 to 
1.577 
98% 0.224 
0.22 
C-statistic 0.711 (0.691 to 
0.732) 
0.662 to 
0.761 
43% 0.017 
D-statistic 0.332 (0.212 to 
0.452) 
-0.080 to 
0.745 
88% 0.157 
Strategy (3):  
Develop using 
Royston-Parmar model 
and implement with the 
estimated baseline 
hazard from the closest 
geographical country 
Calibration 
slope 
0.961 (0.741 to 
1.181) 
0.148 to 
1.775 
99% 0.313 
0.15 
C-statistic 0.710 (0.687 to 
0.734) 
0.653 to 
0.767 
50% 0.020 
D-statistic 0.330 (0.211 to 
0.450) 
-0.068 to 
0.728 
87% 0.151 
 
* defined by a C-statistic≥0.7 and an calibration slope between 0.9 and 1.1 
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Appendix: Brief explanation of key statistical concepts considered in the article 
 
C-statistic 
A measure of a prediction model's discrimination (separation) between those with and 
without an event (outcome), which can be calculated for either binary or survival outcome 
data [20, 21]. Also known as the concordance index or, for binary outcomes, the area under 
the receiver operating characteristic (ROC) curve. It gives the probability that for any 
randomly selected pair of individuals, one with and one without the event (outcome), the 
model assigns a higher probability to the individual with the event (outcome). A value of 1 
indicates the model has perfect discrimination, whilst a value of 0.5 indicates the model 
discriminates no better than chance. For the DVT model we used the ‘roctab’ module in 
STATA to calculate the C-statistic, whilst for the breast cancer model we used ‘stcstat2’ to 
calculate Harrell’s C-statistic. 
 
D-statistic 
A measure of discrimination for time-to-event outcomes [22]. This can be interpreted as the 
log hazard ratio comparing two equally sized groups defined by dichotomising at the median 
value of the prognostic index from the developed model (where the prognostic index is 
defined by the combined predictor effects in the developed model, i.e. beta1*X1 + beta2*X2 
+ ...). Higher values for the D-statistic indicate greater discrimination, and an increase of 0.1 
over other risk scores is suggested to be a good indicator of improved prognostic separation 
[10]. For the breast cancer model, the D-statistic in the external validation study was 
calculated using the ‘str2d’ module [40] in STATA after fitting the Royston-Parmar model in 
our development data using the ‘stpm2’ module [38]. 
 
Calibration slope 
This is a measure of agreement between observed and predicted risk of the event (outcome) 
across the whole range of predicted values [1, 20]. For example, if a prediction model is 
developed using logistic regression it is of the form: 
logit(p) = alpha + beta1*X1 + beta2*X2 + ... 
Then the predicted probability (P-pred) is derived using 
 
 P-pred = exp(alpha + beta1*X1 + beta2*X2 + ...) / [1 + exp(alpha + beta1*X1 + beta2*X2 + ...)] 
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In the validation data, fitting the model 
 
    logit(p) = delta0 + delta1*(logit(P-pred))  
 
is used to calculate the calibration slope (delta1), which should ideally be 1 (though a value 
of 1 does not by itself confirm calibration is perfect [48]).   
In the breast cancer example in our article, we used a flexible parametric survival model to 
develop the prediction model, using the Royston-Parmar approach where the log cumulative 
hazard function is modelled using restricted cubic splines [37-39], with four knots chosen. To 
estimate calibration slope of the developed model, we fitted the following model in each 
external validation study: 
                lnH(t) = gamma0+gamma1*z1+gamma2*z2+gamma3*z3 +b*X 
where b is the calibration slope, lnH(t) is the log cumulative hazard function over time, t, and 
the gamma and z terms define the knots and the baseline lnH(t). The 
(gamma1*z1+gamma2*z2+gamma3*z3) value was forced to be that from the developed 
model; the X value for each patient corresponds to their value of the prognostic index from 
the developed model (i.e. Beta1*X1 + Beta2*X2 + ...); and the gamma0 value is dependent 
on the implementation strategy used. In strategy (1) gamma0 is newly estimated in the 
external validation study (akin to recalibration). In strategy (2) gamma0 is forced to be a 
weighted (meta-analysis) average of all the study-specific gamma0 estimates from the 
developed model. In strategy (3) the gamma0 value is forced to be the gamma0 estimate for 
the nearest country available in the developed model. 
 
Calibration-in-the-large 
This is an overall measure of calibration,[1] defined by fitting in the validation dataset 
 
   logit(p) = alpha0 + offset 
 
where alpha0 is the calibration-in-the-large and the offset term is equal to logit(P-pred) 
 
Expected/Observed number of events (E/O) 
This is another measure of calibration, closely related to the calibration-in-the-large, but more 
intuitive to interpret. It provides the ratio of the total expected events (outcomes) to the total 
observed events (outcomes). It can be obtained by summing all predicted probabilities in the 
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validation dataset and dividing by the number of observed events. An ideal value is 1. Values 
less than 1 indicate the model is under-predicting the total number of events in the 
population, whilst values above 1 indicate it is over-predicting the total events in the 
population.   
 
Non-parametric bootstrapping to obtain variance-covariance matrix of performance 
estimates 
Consider a single external validation study. Bootstrapping uses the IPD from this study and 
randomly selects one patient with replacement, then randomly selects a second patient with 
replacement, and repeats until the same sample size is obtained as in the original study. This 
process is repeated b times, so that b bootstrap samples are obtained. Then, in each of the 
bootstrap samples the performance statistics of the developed model are estimated (e.g. Yi1 
could be the estimated C-statistic and Yi2 could be the estimated calibration slope estimate in 
study i). This produces b values for each performance statistic. The observed variance of the 
b values for each statistic estimates their variance (i.e. it gives Si12 , the variance of Yi1 , etc). 
Similarly, the observed correlation across the b samples for each pair of validation statistics 
estimates their within-study correlation (i.e. it gives ),Wi(ρ 21 , the within-study correlation 
between Yi1 and Yi2 etc). 
 
Bivariate model 
When there are two performance measures of interest (e.g. C-statistic and calibration slope), 
the general multivariate meta-analysis of equation (3) can be simplified to the following 
bivariate meta-analysis: 
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Supplemental Material (Online Only) 
 
 
 
 
 
Supplementary material 1: Example of SAS syntax to derive joint probabilities of model 
performance with regard to two performance measures. 
 
The joint probability of 'good' performance in a new population is obtained below by 
calculating the proportion of 1000000 samples drawn from the approximate posterior 
bivariate t-distribution (with k - 2 d.f.; k = no. of studies). The parameters values to use are 
derived from the estimates of the mean vector and its variance-covariance matrix, and the 
between-study variance-covariance matrix, following REML estimation of multivariate meta- 
analysis equation (3). SAS code is provided below based on using the 'RANDMVT' module . 
Alternatively this can be performed using the “mnormt” package in R software [32]. 
 
/* Breast cancer example: strategy (1)*/ 
proc iml;
 
load module=randmvt; 
/* set random number seed */
 
call randseed(1);
 
/* define number of samples to take */ 
N=100000; 
/* enter degrees of freedom (no. of studies minus 2)*/ 
DF = 6; 
/* Define the means of the posterior distribution to be the meta-analysis mean 
estimates (mu) for the C-statistic and calibration slope*/ 
Mean = {0.711 1.003};
 
/* Define the variance-covariance matrix S for the posterior distribution by: 
V_11 = Variance for C-statistic = tau1-squared + var(mu1) 
V_22 = Variance for calibration slope = tau2-squared + var(mu2)
 
V_12 = V_21 = Covariance of the C-statistic and calibration slope = tau12 +
 
cov(mu1,mu2)
 
(where tau1 and tau2 are the between-study SD for the C-statistic and the 
calibration slope, respectively; mu1 and mu2 are the mean estimates of the C- 
statistic and the calibration slope, respectively; var(mu1) and var(mu2) are the 
variances of the estimates mu1 and mu2, respectively; tau12 is the between-study 
covariance; and cov(mu1,mu2) is the covariance of the estimates of mu1 and mu2) */ 
S = {0.00048 0.000611, 0.000611 0.000958}; 
/* derive the samples and define them by x*/ 
x = RANDMVT( N, DF, Mean, S );
 
/* show the 1000 pair of values generated if on interest*/
 
print x;
 
 
/* convert x to a dataset called samples */ 
create samples from x;
 
append from x;
 
quit;
 
 
/* Create a second dataset that identifies whether 'good' performance was obtained 
for each sample within x - here 'good' is defined by the C-statistic > 0.7 and the 
calibration slope between 0.9 and 1,1 */ 
data samples2; 
set samples; 
/* C-statistic criteria */
 
if col1 > 0.7 then y =1;
 
/* calibration criteria */ 
if col2 > 0.9 then z1 = 1; 
if col2 < 1.1 then z2 = 1; 
/* joint criteria */ 
if y=1 and z1=1 and z2 =1 then accept=1;
 
else accept=0;
 
run;
 
 
/* Calculate the joint probability of good performance, simply by the mean value of 
the 'accept' variable - which is the proportion of samples that had the 'good' 
performance */ 
proc means;
 
vars accept; 
run;
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Study used 
for external 
validation 
Study-specific intercept (DUL) Age Sex Calf 
(β�?  �?  �?  Study  Study Study Study Study  Study Study Study  Study  Study Study Study 1 2 3 4 5 6 7 8 9 10 11 12 
Study 1 
Study 2 
Study 3 
Study 4 
Study 5 
Study 6 
Study 7 
Study 8 
Study 9 
Study 10 
Study 11 
Study 12 
- -1.256  -2.528  -1.807  -2.511  -2.316 -3.061  -1.839  -2.165  -2.339  -2.038  -2.788 
-2.694  - -2.555  -1.823  -2.538  -2.338 -3.080  -1.857  -2.192  -2.353  -2.059  -2.817 
-2.670  -1.253  - -1.805  -2.504  -2.312 -3.062  -1.840  -2.157  -2.336  -2.033  -2.779 
-2.604  -1.191  -2.443  - -2.426  -2.245 -3.005  -1.785  -2.082  -2.289  -1.967  -2.700 
-2.682  -1.265  -2.538  -1.814  - -2.324 -3.070  -1.849  -2.173  -2.343  -2.045  -2.797 
-2.672  -1.255  -2.529  -1.811  -2.508  - -3.066  -1.843  -2.161  -2.343  -2.041  -2.783 
-2.672  -1.255  -2.529  -1.810  -2.509  -2.319 - -1.842  -2.162  -2.342  -2.040  -2.784 
-2.677  -1.260  -2.532  -1.812  -2.513  -2.321 -3.068  - -2.166 -2.342  -2.042  -2.788 
-2.660  -1.245  -2.515  -1.797  -2.498  -2.304 -3.050  -1.828  - -2.329  -2.026  -2.777 
-2.677  -1.260  -2.531  -1.809  -2.515  -2.318 -3.066  -1.844  -2.168  - -2.039  -2.791 
-2.678  -1.261  -2.533  -1.812  -2.515  -2.321 -3.069  -1.847  -2.167  -2.342  - -2.790 
-2.672  -1.256  -2.528  -1.808  -2.509  -2.317 -3.064  -1.841  -2.162  -2.339  -2.038  - 
0.372 0.606 1.304 
0.370 0.624 1.344 
0.400 0.556 1.286 
0.366 0.513 1.197 
0.387 0.579 1.315 
0.409 0.589 1.277 
0.401 0.594 1.283 
0.403 0.572 1.294 
0.350 0.611 1.300 
0.381 0.572 1.313 
0.399 0.565 1.301 
0.391 0.585 1.293 
 
 
 
 
Supplementary  material 2: Model parameter estimates for the fitted DVT model to be implemented using strategy (3), which fits a logistic 
 
regression model in each cycle of the internal-external cross-validation approach to obtain predictor effects and study-specific intercepts. 
 
 
1) (β2) (β3 ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Bold numbers represent the intercept used for external validation in the excluded study for strategy (3), where the intercept from the study 
with the closest prevalence was selected. 
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Supplementary material 3(a): Estimates (standard errors) of the calibration and discrimination performance of the DVT model developed in 
each cycle of the internal-external cross-validation approach, for the three implementation strategies 
 
 
Study 
used for 
external 
validation 
 
Strategy (1): 
Develop using logistic regression and apply with 
intercept estimated in external validation study 
 
CITL  Calibration 
slope Log(E/O)  C-statistic 
Strategy (2): 
Develop using logistic regression and apply with 
average study intercept taken from developed 
model 
Calibration CITL  
slope Log(E/O)  C-statistic 
Strategy (3): 
Develop using logistic regression and apply with 
intercept taken from a study used in development 
data with a similar prevalence 
 
CITL  Calibration  Log(E/O)  C-statistic 
slope 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
-0.172  0.903 0.140 0.678 
(0.098)  (0.131)  (0.080)  (0.024) 
-0.051   0.741  0.028  0.653 
(0.079)  (0.100)  (0.042)  (0.019) 
-0.172  1.418 0.135 0.761 
(0.224)  (0.397)  (0.174)  (0.055) 
-0.084   1.432  0.060  0.735 
(0.054)  (0.100)  (0.039)  (0.014) 
-0.185   0.742  0.141  0.649 
(0.122)  (0.164)  (0.094)  (0.031) 
-0.149   1.030  0.112  0.699 
(0.082)  (0.114)  (0.062)  (0.021) 
-0.178  1.017 0.156 0.694 
(0.090)  (0.117)  (0.080)  (0.023) 
-0.115   0.932  0.081  0.663 
(0.133)  (0.189)  (0.093)  (0.035) 
-0.139   0.994  0.098  0.690 
(0.068)  (0.099)  (0.048)  (0.017) 
-0.127   0.695  0.103  0.636 
(0.150)  (0.215)  (0.122)  (0.037) 
-0.135   0.921  0.094  0.701 
(0.111)  (0.140)  (0.078)  (0.026) 
-0.197  0.936 0.160 0.673 
(0.191)  (0.269)  (0.155)  (0.048) 
-0.440  0.905 0.349 0.678 
(0.098)  (0.136)  (0.081)  (0.025) 
1.105  0.745  -0.709   0.653 
(0.078)  (0.100)  (0.043)  (0.019) 
-0.292  1.396 0.223 0.756 
(0.225)  (0.405)  (0.176)  (0.057) 
0.488  1.434  -0.367   0.736 
(0.057)  (0.099)  (0.040)  (0.014) 
-0.267   0.744  0.201   0.649 
(0.125)  (0.165)  (0.096)  (0.032) 
-0.055   1.044  0.042   0.701 
(0.084)  (0.119)  (0.064)  (0.022) 
-0.877  1.020 0.732 0.694 
(0.089)  (0.122)  (0.078)  (0.023) 
0.464  0.936  -0.340   0.663 
(0.129)  (0.192)  (0.090)  (0.034) 
0.118  0.991  -0.084   0.689 
(0.073)  (0.096)  (0.052)  (0.017) 
-0.081   0.693  0.066   0.635 
(0.144)  (0.219)  (0.116)  (0.038) 
0.258  0.921  -0.185   0.700 
(0.111)  (0.145)  (0.078)  (0.026) 
-0.570  0.923 0.440 0.671 
(0.190)  (0.264)  (0.155)  (0.048) 
0.114 0.905 -0.094  0.678 
(0.094)  (0.132)  (0.078)  (0.024) 
0.583  0.736  -0.344   0.652 
(0.084)  (0.102)  (0.045)  (0.019) 
-0.042  1.390 0.036 0.755 
(0.223)  (0.408)  (0.173)  (0.057) 
0.031  1.434  -0.022   0.736 
(0.057)  (0.102)  (0.040)  (0.014) 
0.016  0.749  -0.011   0.650 
(0.121)  (0.159)  (0.093)  (0.031) 
0.187  1.035  -0.144   0.700 
(0.084)  (0.119)  (0.063)  (0.022) 
-0.399  1.014 0.344 0.693 
(0.090)  (0.123)  (0.080)  (0.024) 
-0.038   0.943  0.028  0.665 
(0.132)  (0.192)  (0.092)  (0.034) 
-0.132   0.996  0.093  0.690 
(0.070)  (0.104)  (0.050)  (0.017) 
0.447  0.699  -0.373   0.637 
(0.146)  (0.208)  (0.119)  (0.036) 
0.132  0.916  -0.093   0.700 
(0.110)  (0.140)  (0.077)  (0.026) 
-0.458  0.930 0.359 0.672 
(0.193)  (0.256)  (0.157)  (0.046) 
Note: CITL refers to calibration-in-the-large and log(E/O) refers to log of the Expected/Observed number of events. 
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Supplementary material 3(b): Within-study correlations (ρWi ), obtained through 
bootstrapping, between performance statistics estimated for the DVT model in each cycle of 
the internal-external cross-validation approach, for the three implementation strategies 
 
 
 
Study 
CITL & 
calibration 
slope 
 
CITL & 
log(E/O) 
 
CITL & 
C-statistic 
Calibration 
slope & 
log(E/O) 
Calibration 
slope & 
C-statistic 
 
Log(E/O) & 
C-statistic 
 
 
 
Strategy (1): 
Develop using 
logistic regression 
and apply with 
intercept estimated 
in external 
validation study 
 
 
 
 
 
Strategy (2): 
Develop using 
logistic regression 
and apply with 
average study 
intercept taken 
from developed 
model 
 
 
 
 
Strategy (3): 
Develop using 
logistic regression 
and apply with 
intercept taken 
from a study used 
in development 
data with a similar 
prevalence 
1 -0.006  -1.000  -0.022  0.006 0.961 0.021 
2 -0.032  -1.000  -0.046  0.033 0.977 0.046 
3 -0.001  -0.999  0.009 0.001 0.955 -0.011 
4 0.118 -1.000  0.045 -0.117  0.919 -0.045 
5 0.046 -1.000  0.029 -0.046  0.983 -0.029 
6 -0.010  -1.000  -0.045  0.011 0.948 0.043 
7 0.047 -1.000  0.002 -0.047  0.912 -0.003 
8 0.071 -1.000  0.032 -0.072  0.953 -0.034 
9 -0.005  -1.000  -0.011  0.005 0.980 0.011 
10 0.108 -1.000  0.064 -0.108  0.900 -0.064 
11 0.000 -1.000  -0.025  0.002 0.956 0.026 
12 -0.035  -1.000  -0.029  0.036 0.980 0.030 
1 -0.051  -1.000  -0.054  0.053 0.960 0.054 
2 0.046 -0.990  0.037 -0.054  0.976 -0.035 
3 -0.051  -0.999  -0.037  0.052 0.958 0.037 
4 0.062 -0.999  -0.009  -0.065  0.928 0.014 
5 0.069 -1.000  0.055 -0.069  0.981 -0.056 
6 0.031 -1.000  -0.013  -0.031  0.959 0.013 
7 0.018 -0.999  -0.025  -0.013  0.923 0.025 
8 0.105 -0.999  0.042 -0.106  0.951 -0.038 
9 0.074 -1.000  0.068 -0.074  0.976 -0.068 
10 0.035 -1.000  0.012 -0.034  0.895 -0.012 
11 0.053 -1.000  0.015 -0.052  0.953 -0.012 
12 0.000 -0.999  -0.001  -0.003  0.981 -0.003 
1 0.005 -1.000  -0.012  -0.004  0.963 0.013 
2 -0.006  -0.997  -0.033  0.002 0.978 0.034 
3 -0.053  -0.999  -0.049  0.054 0.959 0.050 
4 0.082 -1.000  0.015 -0.082  0.925 -0.014 
5 0.034 -1.000  0.022 -0.033  0.982 -0.022 
6 0.063 -1.000  0.020 -0.065  0.956 -0.019 
7 -0.014  -1.000  -0.025  0.015 0.925 0.025 
8 -0.002  -1.000  -0.052  0.001 0.954 0.051 
9 -0.010  -1.000  -0.021  0.011 0.981 0.021 
10 0.020 -0.999  -0.043  -0.024  0.892 0.043 
11 0.038 -1.000  -0.001  -0.040  0.956 0.000 
12 -0.036  -0.999  -0.041  0.036 0.980 0.039 
Note: CITL refers to calibration-in-the-large and log(E/O) refers to log of the Expected/Observed number of 
events. 
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Supplementary  material 4(a): Estimates (standard errors) of calibration and discrimination performance for the breast cancer model in each 
 
cycle of the internal-external cross-validation approach, for the three implementations strategies 
 
 
 
 
Study 
excluded for 
external 
validation 
 
 
 
 
C-statistic1 
 
 
 
 
D-statistic1 
 
 
Strategy (1): Develop 
using Royston- Parmar 
model and implement 
with baseline hazard 
estimated in validation 
study 
Calibration slope2 
Strategy (2): 
Develop using Royston-
Parmar  model and 
implement with the 
estimated average 
baseline hazard in 
develop model 
 
 
Strategy (3): Develop 
using Royston- Parmar 
model and implement 
with the estimated 
baseline hazard from the 
closest geographical 
country 
 
1 0.697 (0.008) 0.493 (0.027) 0.977 (0.012) 1.049 (0.012) 0.805 (0.012) 
2 0.701 (0.036) 0.420 (0.117) 1.002 (0.057) 1.066 (0.057) 1.414 (0.056) 
3 0.715 (0.023) 0.106 (0.056) 1.026 (0.036) 0.578 (0.037) 0.405 (0.037) 
4 0.735 (0.068) 0.326 (0.187) 0.991 (0.097) 0.870 (0.098) 0.919 (0.097) 
5 0.666 (0.050) 0.238 (0.168) 0.946 (0.088) 1.168 (0.086) 1.184 (0.086) 
6 0.682 (0.017) 0.182 (0.041) 0.969 (0.037) 0.896 (0.038) 0.951 (0.037) 
7 0.781 (0.027) 0.280 (0.063) 1.054 (0.052) 0.996 (0.053) 0.794 (0.054) 
8 0.722 (0.016) 0.541 (0.058) 1.035 (0.030) 1.315 (0.029) 1.197 (0.030) 
 
1 The C-statistic and D-statistic only depend on the prognostic index (see Appendix). As the prognostic index (beta terms) from the developed 
model is not dependant on the implementation strategy, the C-statistic and D-statistic estimates are identical regardless of the implementation 
strategy used. 
2 obtained as defined in the Appendix. 
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C-statistic & 
D-statistic 
C-statistic & 
Calibration 
slope 
(strategy (1)) 
C-statistic & 
Calibration 
slope 
(strategy (2)) 
C-statistic & 
Calibration 
slope 
(strategy (3)) 
D-statistic & 
Calibration 
slope 
(strategy (1)) 
D-statistic & 
Calibration 
slope 
(strategy (2)) 
D-statistic & 
Calibration 
slope 
(strategy (3)) 
 
0.842 
 
0.334 
 
0.325 
 
0.349 
 
0.677 
 
0.663 
 
0.704 
0.827 0.303 0.307 0.324 0.662 0.664 0.668 
0.702 0.218 0.237 0.240 0.661 0.688 0.691 
0.762 0.300 0.294 0.297 0.782 0.777 0.779 
0.834 0.469 0.468 0.468 0.668 0.661 0.660 
0.807 0.438 0.451 0.442 0.750 0.764 0.754 
0.612 0.276 0.276 0.274 0.817 0.821 0.832 
0.812 0.199 0.166 0.183 0.625 0.573 0.599 
 
 
 
 
Supplementary material 4(b): Within-study correlations (ρWi), obtained using bootstrapping, between performance statistics estimated for the 
breast cancer model in each internal-external cross-validation cycle, for each implementation strategy 
 
 
 
 
Country 
 
 
 
1 
2 
3 
4 
5 
6 
7 
8 
Strategy (1): Baseline hazard estimated in external validation dataset. 
Strategy (2): Average baseline hazard from developed model. 
Strategy (3): Baseline hazard from country included in the development, closest in proximity. 
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Supplementary material 5: Trivariate random-effects meta-analysis results of calibration and 
discrimination performance for the breast cancer model excluding Study 3, for implementation 
strategy (2) 
 
 
 
 
 
Strategy Validation 
statistic 
 
 
Pooled 
estimate 
(95% CI) 
 
 
95% 
prediction 
interval 
 
 
I- 
squared 
 
 
Estimate 
of τ 
Joint 
probability 
of good* 
performance 
in a new 
population 
 
Strategy (2) 
including Study 3: 
Develop using 
 
Calibration 
slope 
 
0.994 (0.835 
to 1.153) 
 
0.711 (0.691 
 
0.411 to 
1.577 
 
98% 0.224 
Royston-Parmar 
model and apply with 
the estimated average 
C-statistic to 0.732) 0.662 to 0.76 43% 0.017 0.22 
baseline hazard from 
developed model 
D-statistic 0.332 (0.212 to 0.452)
 
-0.08 to
 
0.744 
88% 0.157 
 
Strategy (2) 
excluding Study 3: 
Develop using 
 
Calibration 
slope 
 
0.999 (0.883 
to 1.114) 
 
0.712 (0.688 
 
0.594 to 
1.404 
 
95% 0.146 
Royston-Parmar 
model and apply with 
the estimated average 
C-statistic 0.650 to 
to 0.735) 0.773 
52% 0.021  0.32 
baseline hazard from 
developed model 
D-statistic 0.372 (0.256 to 0.490)
 
-0.014 to
 
0.760 
85% 0.138 
 
 
 
* defined by a C-statistic≥0.7 and a calibration slope between 0.9 and 1.1 
